An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2625-2630

  Korse, C M ^a   Taal, B G ^a   Bonfrer, J M G ^a   Vincent, A ^a   Van velthuysen, M L ^a   Baas, P ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Chromogranin A; Diagnosis; Neuroendocrine tumours; Progastrin releasing peptide; Prognosis; Survival analysis

Indexed keywords

CHROMOGRANIN A; PROGASTRIN RELEASING PEPTIDE; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIATED NEUROENDOCRINE TUMOR; FEMALE; HIGH RISK PATIENT; HUMAN; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GASTRIN-RELEASING PEPTIDE; GASTROINTESTINAL NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 82355172693     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr007     Document Type: Article

References (33)

1. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000; 62 (Suppl 1): 33-38.
2. Sondenaa K, Sen J, Heinle F et al. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg 2004; 28(9): 890-895.
3. Korse CM, Taal BG, de Groot CA et al. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009; 27(26): 4293-4299.
4. Korse CM, Bonfrer JM, Aaronson NK et al. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology 2009; 89(3): 296-301.
5. Giovanella L, Ceriani L, Lumastro C, Ghelfo A. False-positive serum chromogranin A assay due to heterophile antibody interference. Clin Chim Acta 2007; 379(1-2): 171-172.
6. Giusti M, Sidoti M, Augeri C et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004; 150(3): 299-303.
7. Molina R. ProGRP: a new biomarker for small cell lung cancer. Eur J Clin Med Oncol 2010; 2(1): 1-8.
8. Wojcik E, Kulpa JK, Sas-Korczynska B et al. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res 2008; 28(5B): 3027-3033.
9. McDonald TJ, Jornvall H, Nilsson G et al. Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem Biophys Res Commun 1979; 90(1): 227-233.
10. Sunday ME, Choi N, Spindel ER et al. Gastrin-releasing peptide gene expression in small cell and large cell undifferentiated lung carcinomas. Hum Pathol 1991; 22(10): 1030-1039.
11. Lamy PJ, Grenier J, Kramar A, Pujol JL. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 2000; 29(3): 197-203.
12. Molina R, Auge JM, Bosch X et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol 2009; 30(3): 121-129.
13. Niho S, Nishiwaki Y, Goto K et al. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000; 27(3): 159-167.
14. Nordlund MS, Bjerner J, Warren DJ et al. Progastrin-releasing peptide: stability in plasma/serum and upper reference limit. Tumour Biol 2008; 29(3): 204-210.
15. Sunaga N, Tsuchiya S, Minato K et al. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 1999; 57(2): 143-148.
16. Molina R, Auge JM, Alicarte J et al. Pro-gastrin-releasing peptide in patients with benign and malignant diseases. Tumour Biol 2004; 25(1-2): 56-61.
17. Solcia E, Kloppel G, Sobin L. Histological Typing of Endocrine Tumours. WHO International Histological Classification of Tumours, 2nd edition. Berlin, Germany: Springer 2000.
18. Travis W, Colby T, Corrin B et al. Histological Typing of Lung and Pleural Tumours. WHO International Histological Classification of Tumours, 3rd edition. Berlin, Germany: Springer 1999.
19. Klimstra DS, Modlin IR, Coppola D et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39(6): 707-712.
20. Rindi G, Kloppel G, Couvelard A et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451(4): 757-762.
21. Yoshimura T, Fujita K, Kinukawa H et al. Development and analytical performance evaluation of an automated chemiluminescent immunoassay for pro-gastrin releasing peptide (ProGRP). Clin Chem Lab Med 2009; 47(12): 1557-1563.
22. Horowitz GL, Altail S, Boyd JC et al. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory, 3rd edition. Pennsylvania, PA: Clinical and Laboratory Standards Institute 2008.
23. Fraley C, Raftery AE. Model-based clustering, discriminant analysis, density estimation. J Am Stat Assoc 2002; 97(458): 611-631.
24. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model, 1st edition. New York: Springer-Verlag 2000.
25. Molina R, Filella X, Auge JM. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004; 37(7): 505-511.
26. Stieber P, Dienemann H, Schalhorn A et al. Pro-gastrin-releasing peptide (ProGRP)-a useful marker in small cell lung carcinomas. Anticancer Res 1999; 19(4A): 2673-2678.
27. Yoshimura T, Fujita K, Kawakami S et al. Stability of pro-gastrin-releasing peptide in serum versus plasma. Tumour Biol 2008; 29(4): 224-230.
28. Modlin IM, Gustafsson BI, Moss SF et al. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17: 2427-2443.
29. Rijksinstituut voor Volksgezondheid en Milieu. Nationale atlas voor de volksgezondheid. 2008; http://www.zorgatlas.nl/ (14 March 2011, date last accessed).
30. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005; 10(2): 123-131.
31. Granberg D, Eriksson B, Wilander E et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001; 12(10): 1383-1391.
32. Steinmuller T, Kianmanesh R, Falconi M et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87(1): 47-62.
33. Wirth LJ, Carter MR, Janne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004; 44(2): 213-220.